Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Naltrexone: Has Promise, Needs Study

Naltrexone: Has Promise, Needs Study Naltrexone: Has Promise, Needs Study By Jill Stein AIDS and one with ARC, from 23 to 58 years of age, who received daily miniscule doses of naltrexone as their sole therapy. Over a four- to eight-month pe¬ riod after the start of treatment, 23 had a significant drop in their alpha-interferon levels. Alpha-interferon is a substance that occurs naturally in the body and has been shown by some investigators to re¬ duce pain. Continuously high levels are found in AIDS patients. The 23 patients, classified as "re¬ sponders," had only eight opportunistic infections during the trial, compared to 19 that occurred in the 16 patients whose alpha-interferon levels remained unusu¬ ally high despite treatment. These pa¬ tients were dubbed "nonresponders." In addition, of the eight opportunistic infec¬ tions in the responder group, four were mild episodes of Pneumocystis carinii pneumonia, and three cases occurred be¬ fore alpha-interferon levels had dropped from their values recorded at the start of the study. The remaining four opportu¬ nistic infections in the responder group and all 19 in the nonresponder group were life-threatening and in most cases fatal. Additionally, the data showed that responders survived longer. Four (17 percent) of the responders http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AIDS Patient Care Mary Ann Liebert

Naltrexone: Has Promise, Needs Study

AIDS Patient Care , Volume 1 (3) – Dec 1, 1987

Naltrexone: Has Promise, Needs Study

AIDS Patient Care , Volume 1 (3) – Dec 1, 1987

Abstract

Naltrexone: Has Promise, Needs Study By Jill Stein AIDS and one with ARC, from 23 to 58 years of age, who received daily miniscule doses of naltrexone as their sole therapy. Over a four- to eight-month pe¬ riod after the start of treatment, 23 had a significant drop in their alpha-interferon levels. Alpha-interferon is a substance that occurs naturally in the body and has been shown by some investigators to re¬ duce pain. Continuously high levels are found in AIDS patients. The 23 patients, classified as "re¬ sponders," had only eight opportunistic infections during the trial, compared to 19 that occurred in the 16 patients whose alpha-interferon levels remained unusu¬ ally high despite treatment. These pa¬ tients were dubbed "nonresponders." In addition, of the eight opportunistic infec¬ tions in the responder group, four were mild episodes of Pneumocystis carinii pneumonia, and three cases occurred be¬ fore alpha-interferon levels had dropped from their values recorded at the start of the study. The remaining four opportu¬ nistic infections in the responder group and all 19 in the nonresponder group were life-threatening and in most cases fatal. Additionally, the data showed that responders survived longer. Four (17 percent) of the responders

Loading next page...
 
/lp/mary-ann-liebert/naltrexone-has-promise-needs-study-dhZg2t4YUS
Publisher
Mary Ann Liebert
Copyright
Copyright 1987 Mary Ann Liebert, Inc.
ISSN
0893-5068
eISSN
1557-7449
DOI
10.1089/apc.1987.1.24
Publisher site
See Article on Publisher Site

Abstract

Naltrexone: Has Promise, Needs Study By Jill Stein AIDS and one with ARC, from 23 to 58 years of age, who received daily miniscule doses of naltrexone as their sole therapy. Over a four- to eight-month pe¬ riod after the start of treatment, 23 had a significant drop in their alpha-interferon levels. Alpha-interferon is a substance that occurs naturally in the body and has been shown by some investigators to re¬ duce pain. Continuously high levels are found in AIDS patients. The 23 patients, classified as "re¬ sponders," had only eight opportunistic infections during the trial, compared to 19 that occurred in the 16 patients whose alpha-interferon levels remained unusu¬ ally high despite treatment. These pa¬ tients were dubbed "nonresponders." In addition, of the eight opportunistic infec¬ tions in the responder group, four were mild episodes of Pneumocystis carinii pneumonia, and three cases occurred be¬ fore alpha-interferon levels had dropped from their values recorded at the start of the study. The remaining four opportu¬ nistic infections in the responder group and all 19 in the nonresponder group were life-threatening and in most cases fatal. Additionally, the data showed that responders survived longer. Four (17 percent) of the responders

Journal

AIDS Patient CareMary Ann Liebert

Published: Dec 1, 1987

There are no references for this article.